Skip to search formSkip to main contentSkip to account menu

KW 2170

Known as: KW-2170 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AcridinesPyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A phase II trial of weekly i.v. KW‐2170 in advanced castrate‐resistant prostate cancer
Aim:  KW‐2170 is a novel pyrazoloacridone derivative that intercalates nucleic acids. It has promising in vitro properties… 
2004
2004
Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors
PurposeThe primary purposes of this study were to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), to… 
2002
2002
KW-2170 (Kyowa Hakko Kogyo).
  • C. Verschraegen
  • IDrugs : the investigational drugs journal
  • 2002
  • Corpus ID: 26321496
The pyrazoloacridone, KW-2170, an alkylating agent and topoisomerase II inhibitor, is being developed by Kyowa Hakko Kogyo as a… 
2002
2002
Determination of the anticancer drug KW-2170, a pyrazoloacridone derivative, and its metabolites in human and dog plasma by high-performance liquid chromatography using an electrochemical detector.
1998
1998
Antitumor activity of KW‐2170, a novel pyrazoloacridone derivative
5-(3-Aminopropyl)amino-7,10-dihydroxy-2-(2-hydroxethyl)-aminoethyl-6H-pyrazolo[4,5,1-de]acridin-6-one dihydroxychloride (KW-2170… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)